Evolent Health, Inc (NYSE:EVH) – Equities researchers at SunTrust Banks reduced their FY2019 earnings per share estimates for Evolent Health in a note issued to investors on Wednesday. SunTrust Banks analyst S. Draper now anticipates that the technology company will earn $0.41 per share for the year, down from their previous forecast of $0.46. SunTrust Banks currently has a “Buy” rating and a $30.00 target price on the stock.

EVH has been the subject of a number of other research reports. BidaskClub cut shares of Evolent Health from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Robert W. Baird restated an “outperform” rating and issued a $35.00 price objective (up previously from $30.00) on shares of Evolent Health in a research report on Wednesday, June 14th. Leerink Swann reiterated an “outperform” rating and set a $32.00 target price (up previously from $30.00) on shares of Evolent Health in a report on Monday, June 19th. Zacks Investment Research cut Evolent Health from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Finally, Cowen and Company reiterated an “outperform” rating and set a $33.00 target price (down previously from $35.00) on shares of Evolent Health in a report on Wednesday, August 9th. Three analysts have rated the stock with a sell rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Evolent Health presently has an average rating of “Buy” and a consensus price target of $29.33.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/23/suntrust-banks-analysts-cut-earnings-estimates-for-evolent-health-inc-evh.html.

Shares of Evolent Health (NYSE:EVH) traded up 3.40% on Thursday, hitting $16.75. The stock had a trading volume of 1,852,583 shares. The company’s market capitalization is $1.10 billion. The firm has a 50 day moving average price of $17.19 and a 200 day moving average price of $17.19. Evolent Health has a one year low of $14.50 and a one year high of $25.66.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Monday, August 7th. The technology company reported ($0.13) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.13). Evolent Health had a negative return on equity of 6.44% and a negative net margin of 17.57%. The business had revenue of $107.30 million for the quarter, compared to the consensus estimate of $104.45 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share. Evolent Health’s revenue for the quarter was up 89.9% compared to the same quarter last year.

In related news, CEO Steve Wigginton sold 6,000 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $25.07, for a total value of $150,420.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Nicholas Mcgrane sold 1,667 shares of the firm’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $25.42, for a total transaction of $42,375.14. The disclosure for this sale can be found here. Insiders sold a total of 4,366,132 shares of company stock valued at $112,891,200 in the last 90 days. 8.79% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of the stock. FMR LLC lifted its stake in Evolent Health by 117.7% in the 2nd quarter. FMR LLC now owns 9,864,775 shares of the technology company’s stock valued at $250,073,000 after purchasing an additional 5,333,252 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Evolent Health by 7.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 5,438,126 shares of the technology company’s stock valued at $137,857,000 after purchasing an additional 379,185 shares during the last quarter. Vanguard Group Inc. lifted its stake in Evolent Health by 48.9% in the 2nd quarter. Vanguard Group Inc. now owns 3,769,869 shares of the technology company’s stock valued at $95,566,000 after purchasing an additional 1,237,941 shares during the last quarter. Pennant Capital Management LLC lifted its stake in Evolent Health by 2.9% in the 1st quarter. Pennant Capital Management LLC now owns 2,843,021 shares of the technology company’s stock valued at $63,399,000 after purchasing an additional 81,300 shares during the last quarter. Finally, Riverbridge Partners LLC acquired a new stake in Evolent Health in the 2nd quarter valued at about $58,878,000. Institutional investors and hedge funds own 82.51% of the company’s stock.

About Evolent Health

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.